Combinatorial Therapy Approaches for NF2-Deficient Meningiomas
Final rept. 1 JUn 2011-30 May 2013
JOHNS HOPKINS UNIV BALTIMORE MD
Pagination or Media Count:
The aim of our research is to find novel targeted therapy for NF2 patients to provide a new therapeutic option for meningiomas that includes the standard of care radiotherapy. We have successfully selected four small molecule compounds that preferentially inhibit NF2 mutant meningioma cells in vitro. These are FDA approved drugs that are safe for human use. We validated these drugs by using human cell lines and tested their ability to synergize with radiation. We have optimized the use of a CT-guided conformal radiation that can be tested in a meningioma mouse model. The findings from this research project will be valuable for future clinical trials, for testing combinatorial approaches to treat meningioma patients.
- Medicine and Medical Research